drugset

drugset / Trial / NCT00578526

SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial

NCT00578526 ↗

Phase 2 Completed 64 enrolled AHS Cancer Control Alberta Pfizer · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to find out if SU011248 works and if it is safe in patients with advanced transitional cell carcinoma.

Timeline

Start: 2008-04
Primary completion: 2014-07-16
Completion: 2014-07-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Sunitinib	Small molecule	50 mg	Oral

Indications